ABPA
Conditions
Keywords
cytokine, ABPA, Type 2 immune response, PBMC
Brief summary
The main aim of this study is to determine whether the levels of different inflammatory cytokines in the serum and BALF (bronchoalveolar lavage fluid) are relative to the severity and exacerbations of ABPA (allergic bronchopulmonary aspergillosis).
Detailed description
The study would record patients' medical data at baseline and follow them up for different period of time. Updated data would be recorded and blood( or BALF) of the patients would be drawn for tests or stored as whole blood or serum at -80℃ when patients visit the hospital. Then the cytokine (A panel set by the manufacturer) of the serum and BALF would be tested . The secretion ability of peripheral blood mononuclear cells would also be verified. The investigators would then analyze the data and see if any cytokine is relative to the exacerbation or other indicators of the severity of ABPA.
Interventions
None listed
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
For ABPA patients Inclusion Criteria: * Patients diagnosed as allergic bronchopulmonary aspergillosis (ABPA). The diagnosis criteria of ABPA is as following: clinical diagnosis of asthma, elevated total IgE levels (\> 1,000 IU/mL), presence of specific IgE against A fumigatus detected (\> 0.35 kUA/L) or type 1 skin reaction to Aspergillus antigen. Other criteria(at least two of three): Presence of serum IgG antibodies (precipitins) against A. fumigatus; Radiographic pulmonary opacities consistent with ABPA(It might be transient consolidation, nodules, finger-in-glove opacities. Or it could be permanent bronchiectasis and pleuropulmonary fibrosis) Patients who sighed consent forms. For asthma patients: Diagnosis according to GINA. For healthy control: People with ongoing chronic allergic disease such as allergic rhinitis, asthma and allergic dermatitis are excluded.
Exclusion criteria
* Patients who are unwilling to sign the consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cytokines levels | 1 year | The levels of different cytokines in the serum or BALF at the enrollment and during follow up. The relation of different cytokines levels and characteristics of ABPA patients would be analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| High attenuation mucus (HAM) | Once | It is defined objectively on a CT scan as having an attenuation value \> 70 Hounsfield units, visually denser than the paraspinal skeletal muscle |
| Eosinophilia | 1 year | Equal to or more than 500/μl |
| FeNO | 1 year | The fraction of exhaled nitric oxide |
| Exacerbation | 1 year | The worsening of the symptoms of patients, or the new infiltrate of lung under CT scan that is relevant to ABPA, or the elevated serum IgE level. |
| Time to exacerbation | 1 year | The onset date of therapy and the date of the next exacerbation would be recorded to calculate the time to the next exacerbation |
| Level of different cytokine secreting cells | 1 year | PBMC would be stained immediately or co-cultured with PMA/ionmycin before staining for flow cytometry. |
| Phenotypes of ABPA | Once | Patients would be categorized into three phenotypes: ABPA-S (seropositive), ABPA-CB (central bronchiectasis) and ABPA-ORF (other radiologic findings) |
Countries
China
Contacts
Primary ContactJin-fu Xu, MD
Outcome results
None listed